Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
for NSCLC (Non-small Cell Lung Cancer)
Drug: daraxonrasib
39 locations incl. Birmingham
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT06881784·Phase 3·Recruiting